Review



mouse antihuman elf1 polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech mouse antihuman elf1 polyclonal antibody
    <t>ELF1</t> mRNA expression and diagnostic value in GC tissues. (A) ELF1 mRNA expression levels in cancerous tissues (red) and adjacent normal tissues (black) obtained from the GEPIA database. (B) Boxplot of ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software. (C) ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software (linear diagram). (D) ELF1 expression in tissue from the 40 patients with GC was measured using reverse transcription-quantitative PCR. (E) Receiver operating characteristic curve. STAD, stomach adenocarcinoma; GC, gastric cancer; AUC, area under the curve; ELF1, E74-like Factor 1.
    Mouse Antihuman Elf1 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse antihuman elf1 polyclonal antibody/product/Proteintech
    Average 93 stars, based on 9 article reviews
    mouse antihuman elf1 polyclonal antibody - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer"

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    Journal: Experimental and Therapeutic Medicine

    doi: 10.3892/etm.2024.12730

    ELF1 mRNA expression and diagnostic value in GC tissues. (A) ELF1 mRNA expression levels in cancerous tissues (red) and adjacent normal tissues (black) obtained from the GEPIA database. (B) Boxplot of ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software. (C) ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software (linear diagram). (D) ELF1 expression in tissue from the 40 patients with GC was measured using reverse transcription-quantitative PCR. (E) Receiver operating characteristic curve. STAD, stomach adenocarcinoma; GC, gastric cancer; AUC, area under the curve; ELF1, E74-like Factor 1.
    Figure Legend Snippet: ELF1 mRNA expression and diagnostic value in GC tissues. (A) ELF1 mRNA expression levels in cancerous tissues (red) and adjacent normal tissues (black) obtained from the GEPIA database. (B) Boxplot of ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software. (C) ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software (linear diagram). (D) ELF1 expression in tissue from the 40 patients with GC was measured using reverse transcription-quantitative PCR. (E) Receiver operating characteristic curve. STAD, stomach adenocarcinoma; GC, gastric cancer; AUC, area under the curve; ELF1, E74-like Factor 1.

    Techniques Used: Expressing, Diagnostic Assay, Software, Reverse Transcription, Real-time Polymerase Chain Reaction

    ELF1 and MMP9 protein expression levels in GC and adjacent normal tissues as detected by immunohistochemistry. (A) Left, positive ELF1 expression in GC tumor cells (red arrow); right, ELF1 expression in lymphocytes in the GC mesenchyme. (B) Positive MMP9 expression in GC tissues (red arrow). (C) Left, weakly positive ELF1 expression in adjacent normal epithelial cells (green arrow); right, ELF1 expression in lymphocytes in normal mesenchyme. (D) Weakly positive MMP9 expression in adjacent normal tissues (green arrow). Original magnification x400 (scale bars, 50 µm); Smaller figures, original magnification x40 (scale bars, 500 µm). ELF1, E74-like Factor 1; GC, gastric cancer.
    Figure Legend Snippet: ELF1 and MMP9 protein expression levels in GC and adjacent normal tissues as detected by immunohistochemistry. (A) Left, positive ELF1 expression in GC tumor cells (red arrow); right, ELF1 expression in lymphocytes in the GC mesenchyme. (B) Positive MMP9 expression in GC tissues (red arrow). (C) Left, weakly positive ELF1 expression in adjacent normal epithelial cells (green arrow); right, ELF1 expression in lymphocytes in normal mesenchyme. (D) Weakly positive MMP9 expression in adjacent normal tissues (green arrow). Original magnification x400 (scale bars, 50 µm); Smaller figures, original magnification x40 (scale bars, 500 µm). ELF1, E74-like Factor 1; GC, gastric cancer.

    Techniques Used: Expressing, Immunohistochemistry

    Expression of ELF1 and MMP9 by immunohistochemistry in GC and adjacent normal tissues (N=355).
    Figure Legend Snippet: Expression of ELF1 and MMP9 by immunohistochemistry in GC and adjacent normal tissues (N=355).

    Techniques Used: Expressing, Immunohistochemistry

    Association between ELF1 and MMP9 protein expression positivity in tissue microarray according to immunohistochemistry in patients with gastric cancer.
    Figure Legend Snippet: Association between ELF1 and MMP9 protein expression positivity in tissue microarray according to immunohistochemistry in patients with gastric cancer.

    Techniques Used: Expressing, Microarray, Immunohistochemistry

    Association of ELF1 and MMP9 expression by tissue microarray-immunohistochemistry with clinical characteristics in patients with GC.
    Figure Legend Snippet: Association of ELF1 and MMP9 expression by tissue microarray-immunohistochemistry with clinical characteristics in patients with GC.

    Techniques Used: Expressing, Microarray, Cell Differentiation

    Kaplan-Meier survival analyses of patients with GC. (A) ELF1-high patients with GC (green line) exhibited inferior OS compared with those with ELF1-low expression (blue line). (B) MMP9-high patients with GC (green line) had inferior OS compared with that in MMP9-low patients (blue line). (C) Patients with GC and ELF1- and MMP9-high co-expression (purple line) had the worst OS among all groups compared. (D) Patients with the most advanced TNM stage had the shortest survival times. Censored data points indicate patients who were still alive until the end of follow-up. GC, gastric cancer; ELF1, E74-like Factor 1; Cum, cumulative; OS, overall survival.
    Figure Legend Snippet: Kaplan-Meier survival analyses of patients with GC. (A) ELF1-high patients with GC (green line) exhibited inferior OS compared with those with ELF1-low expression (blue line). (B) MMP9-high patients with GC (green line) had inferior OS compared with that in MMP9-low patients (blue line). (C) Patients with GC and ELF1- and MMP9-high co-expression (purple line) had the worst OS among all groups compared. (D) Patients with the most advanced TNM stage had the shortest survival times. Censored data points indicate patients who were still alive until the end of follow-up. GC, gastric cancer; ELF1, E74-like Factor 1; Cum, cumulative; OS, overall survival.

    Techniques Used: Expressing

    Cox regression analysis of prognostic factors for 5-year survival from gastric cancer.
    Figure Legend Snippet: Cox regression analysis of prognostic factors for 5-year survival from gastric cancer.

    Techniques Used: Expressing

    Correlation between ELF1 expression and that of MLH1, ERBB2, PIK3CA, TP53, MMP9, CDH1, TIMP1, VEGFA and KDR in GC tissues according to the GEPIA database. Correlation between ELF1 and (A) MLH1, (B) PIK3CA, (C) CDH1, (D) ERBB2, (E) TP53, (F) MMP9, (G) TIMP1, (H) VEGFA and (I) KDR. TPM, transcripts per kilobase of exon model per million mapped reads; ELF1, E74-like Factor 1; MLH1, MutL homolog 1; ERBB2, erythroblastic leukemia viral oncogene homolog 2; PIK3CA, PI3K subunit α; CDH1, cadherin 1; TIMP1, tissue inhibitors of metalloproteinases; KDR, kinase insert domain receptor.
    Figure Legend Snippet: Correlation between ELF1 expression and that of MLH1, ERBB2, PIK3CA, TP53, MMP9, CDH1, TIMP1, VEGFA and KDR in GC tissues according to the GEPIA database. Correlation between ELF1 and (A) MLH1, (B) PIK3CA, (C) CDH1, (D) ERBB2, (E) TP53, (F) MMP9, (G) TIMP1, (H) VEGFA and (I) KDR. TPM, transcripts per kilobase of exon model per million mapped reads; ELF1, E74-like Factor 1; MLH1, MutL homolog 1; ERBB2, erythroblastic leukemia viral oncogene homolog 2; PIK3CA, PI3K subunit α; CDH1, cadherin 1; TIMP1, tissue inhibitors of metalloproteinases; KDR, kinase insert domain receptor.

    Techniques Used: Expressing

    Connection between ELF1 expression and immune cell infiltration in GC. (A) Correlation analysis of ELF1 expression and the degree of infiltration by the various immune cell types according to TIMER. (B) Infiltration results between high and low expression groups of ELF1. ELF1, E74-like Factor 1; TPM, transcripts per kilobase of exon model per million mapped reads; NK, natural killer.
    Figure Legend Snippet: Connection between ELF1 expression and immune cell infiltration in GC. (A) Correlation analysis of ELF1 expression and the degree of infiltration by the various immune cell types according to TIMER. (B) Infiltration results between high and low expression groups of ELF1. ELF1, E74-like Factor 1; TPM, transcripts per kilobase of exon model per million mapped reads; NK, natural killer.

    Techniques Used: Expressing

    Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.
    Figure Legend Snippet: Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.

    Techniques Used: Expressing, Microarray, Significance Assay

    Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.
    Figure Legend Snippet: Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.

    Techniques Used: Immunohistochemical staining, Expressing



    Similar Products

    mouse antihuman elf1 polyclonal antibody  (Proteintech)
    93
    Proteintech mouse antihuman elf1 polyclonal antibody
    <t>ELF1</t> mRNA expression and diagnostic value in GC tissues. (A) ELF1 mRNA expression levels in cancerous tissues (red) and adjacent normal tissues (black) obtained from the GEPIA database. (B) Boxplot of ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software. (C) ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software (linear diagram). (D) ELF1 expression in tissue from the 40 patients with GC was measured using reverse transcription-quantitative PCR. (E) Receiver operating characteristic curve. STAD, stomach adenocarcinoma; GC, gastric cancer; AUC, area under the curve; ELF1, E74-like Factor 1.
    Mouse Antihuman Elf1 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse antihuman elf1 polyclonal antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    mouse antihuman elf1 polyclonal antibody - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ELF1 mRNA expression and diagnostic value in GC tissues. (A) ELF1 mRNA expression levels in cancerous tissues (red) and adjacent normal tissues (black) obtained from the GEPIA database. (B) Boxplot of ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software. (C) ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software (linear diagram). (D) ELF1 expression in tissue from the 40 patients with GC was measured using reverse transcription-quantitative PCR. (E) Receiver operating characteristic curve. STAD, stomach adenocarcinoma; GC, gastric cancer; AUC, area under the curve; ELF1, E74-like Factor 1.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: ELF1 mRNA expression and diagnostic value in GC tissues. (A) ELF1 mRNA expression levels in cancerous tissues (red) and adjacent normal tissues (black) obtained from the GEPIA database. (B) Boxplot of ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software. (C) ELF1 mRNA expression in 375 GC tissues and 32 GC adjacent tissue samples in the TCGA database as investigated using the R software (linear diagram). (D) ELF1 expression in tissue from the 40 patients with GC was measured using reverse transcription-quantitative PCR. (E) Receiver operating characteristic curve. STAD, stomach adenocarcinoma; GC, gastric cancer; AUC, area under the curve; ELF1, E74-like Factor 1.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing, Diagnostic Assay, Software, Reverse Transcription, Real-time Polymerase Chain Reaction

    ELF1 and MMP9 protein expression levels in GC and adjacent normal tissues as detected by immunohistochemistry. (A) Left, positive ELF1 expression in GC tumor cells (red arrow); right, ELF1 expression in lymphocytes in the GC mesenchyme. (B) Positive MMP9 expression in GC tissues (red arrow). (C) Left, weakly positive ELF1 expression in adjacent normal epithelial cells (green arrow); right, ELF1 expression in lymphocytes in normal mesenchyme. (D) Weakly positive MMP9 expression in adjacent normal tissues (green arrow). Original magnification x400 (scale bars, 50 µm); Smaller figures, original magnification x40 (scale bars, 500 µm). ELF1, E74-like Factor 1; GC, gastric cancer.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: ELF1 and MMP9 protein expression levels in GC and adjacent normal tissues as detected by immunohistochemistry. (A) Left, positive ELF1 expression in GC tumor cells (red arrow); right, ELF1 expression in lymphocytes in the GC mesenchyme. (B) Positive MMP9 expression in GC tissues (red arrow). (C) Left, weakly positive ELF1 expression in adjacent normal epithelial cells (green arrow); right, ELF1 expression in lymphocytes in normal mesenchyme. (D) Weakly positive MMP9 expression in adjacent normal tissues (green arrow). Original magnification x400 (scale bars, 50 µm); Smaller figures, original magnification x40 (scale bars, 500 µm). ELF1, E74-like Factor 1; GC, gastric cancer.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing, Immunohistochemistry

    Expression of ELF1 and MMP9 by immunohistochemistry in GC and adjacent normal tissues (N=355).

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Expression of ELF1 and MMP9 by immunohistochemistry in GC and adjacent normal tissues (N=355).

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing, Immunohistochemistry

    Association between ELF1 and MMP9 protein expression positivity in tissue microarray according to immunohistochemistry in patients with gastric cancer.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Association between ELF1 and MMP9 protein expression positivity in tissue microarray according to immunohistochemistry in patients with gastric cancer.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing, Microarray, Immunohistochemistry

    Association of ELF1 and MMP9 expression by tissue microarray-immunohistochemistry with clinical characteristics in patients with GC.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Association of ELF1 and MMP9 expression by tissue microarray-immunohistochemistry with clinical characteristics in patients with GC.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing, Microarray, Cell Differentiation

    Kaplan-Meier survival analyses of patients with GC. (A) ELF1-high patients with GC (green line) exhibited inferior OS compared with those with ELF1-low expression (blue line). (B) MMP9-high patients with GC (green line) had inferior OS compared with that in MMP9-low patients (blue line). (C) Patients with GC and ELF1- and MMP9-high co-expression (purple line) had the worst OS among all groups compared. (D) Patients with the most advanced TNM stage had the shortest survival times. Censored data points indicate patients who were still alive until the end of follow-up. GC, gastric cancer; ELF1, E74-like Factor 1; Cum, cumulative; OS, overall survival.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Kaplan-Meier survival analyses of patients with GC. (A) ELF1-high patients with GC (green line) exhibited inferior OS compared with those with ELF1-low expression (blue line). (B) MMP9-high patients with GC (green line) had inferior OS compared with that in MMP9-low patients (blue line). (C) Patients with GC and ELF1- and MMP9-high co-expression (purple line) had the worst OS among all groups compared. (D) Patients with the most advanced TNM stage had the shortest survival times. Censored data points indicate patients who were still alive until the end of follow-up. GC, gastric cancer; ELF1, E74-like Factor 1; Cum, cumulative; OS, overall survival.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing

    Cox regression analysis of prognostic factors for 5-year survival from gastric cancer.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Cox regression analysis of prognostic factors for 5-year survival from gastric cancer.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing

    Correlation between ELF1 expression and that of MLH1, ERBB2, PIK3CA, TP53, MMP9, CDH1, TIMP1, VEGFA and KDR in GC tissues according to the GEPIA database. Correlation between ELF1 and (A) MLH1, (B) PIK3CA, (C) CDH1, (D) ERBB2, (E) TP53, (F) MMP9, (G) TIMP1, (H) VEGFA and (I) KDR. TPM, transcripts per kilobase of exon model per million mapped reads; ELF1, E74-like Factor 1; MLH1, MutL homolog 1; ERBB2, erythroblastic leukemia viral oncogene homolog 2; PIK3CA, PI3K subunit α; CDH1, cadherin 1; TIMP1, tissue inhibitors of metalloproteinases; KDR, kinase insert domain receptor.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Correlation between ELF1 expression and that of MLH1, ERBB2, PIK3CA, TP53, MMP9, CDH1, TIMP1, VEGFA and KDR in GC tissues according to the GEPIA database. Correlation between ELF1 and (A) MLH1, (B) PIK3CA, (C) CDH1, (D) ERBB2, (E) TP53, (F) MMP9, (G) TIMP1, (H) VEGFA and (I) KDR. TPM, transcripts per kilobase of exon model per million mapped reads; ELF1, E74-like Factor 1; MLH1, MutL homolog 1; ERBB2, erythroblastic leukemia viral oncogene homolog 2; PIK3CA, PI3K subunit α; CDH1, cadherin 1; TIMP1, tissue inhibitors of metalloproteinases; KDR, kinase insert domain receptor.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing

    Connection between ELF1 expression and immune cell infiltration in GC. (A) Correlation analysis of ELF1 expression and the degree of infiltration by the various immune cell types according to TIMER. (B) Infiltration results between high and low expression groups of ELF1. ELF1, E74-like Factor 1; TPM, transcripts per kilobase of exon model per million mapped reads; NK, natural killer.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Connection between ELF1 expression and immune cell infiltration in GC. (A) Correlation analysis of ELF1 expression and the degree of infiltration by the various immune cell types according to TIMER. (B) Infiltration results between high and low expression groups of ELF1. ELF1, E74-like Factor 1; TPM, transcripts per kilobase of exon model per million mapped reads; NK, natural killer.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing

    Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Expressing, Microarray, Significance Assay

    Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

    doi: 10.3892/etm.2024.12730

    Figure Lengend Snippet: Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.

    Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4 ̊C.

    Techniques: Immunohistochemical staining, Expressing